<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">0372741</journal-id>
<journal-id journal-id-type="pubmed-jr-id">3058</journal-id>
<journal-id journal-id-type="nlm-ta">Clin Pharmacol Ther</journal-id>
<journal-id journal-id-type="iso-abbrev">Clin. Pharmacol. Ther.</journal-id>
<journal-title-group>
<journal-title>Clinical pharmacology and therapeutics</journal-title>
</journal-title-group>
<issn pub-type="ppub">0009-9236</issn>
<issn pub-type="epub">1532-6535</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29171014</article-id>
<article-id pub-id-type="pmc">5805632</article-id>
<article-id pub-id-type="doi">10.1002/cpt.951</article-id>
<article-id pub-id-type="manuscript">NIHMS923123</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The influence of big (clinical) data and genomics on precision medicine and drug development</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Denny</surname>
<given-names>Joshua C.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Van Driest</surname>
<given-names>Sara L.</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wei</surname>
<given-names>Wei-Qi</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Roden</surname>
<given-names>Dan M.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>1</label>Department of Biomedical Informatics, Vanderbilt University Medical Center</aff>
<aff id="A2">
<label>2</label>Department of Medicine, Vanderbilt University Medical Center</aff>
<aff id="A3">
<label>3</label>Department of Pediatrics, Vanderbilt University Medical Center</aff>
<aff id="A4">
<label>4</label>Department of Pharmacology, Vanderbilt University Medical Center</aff>
<author-notes>
<corresp id="FN1">Corresponding Author: Joshua C. Denny, M.D., M.S., Nashville, TN 37232-2730, <email>josh.denny@vanderbilt.edu</email></corresp>
<fn fn-type="COI-statement" id="FN2">
<p>Conflict of Interest: The authors have no competing interests as defined by the American Society for Clinical Pharmacology and Therapeutics, or other interests that might be perceived to influence the results and/or discussion reported in this paper.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>29</day>
<month>11</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>05</day>
<month>2</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="ppub">
<month>3</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>3</month>
<year>2019</year>
</pub-date>
<volume>103</volume>
<issue>3</issue>
<fpage>409</fpage>
<lpage>418</lpage>
<!--elocation-id from pubmed: 10.1002/cpt.951-->
<abstract>
<p id="P1">Drug development continues to be costly and slow, with medications failing due to lack of efficacy or presence of toxicity. The promise of pharmacogenomic discovery includes tailoring therapeutics based on an individual's genetic makeup, rational drug development, and repurposing medications. Rapid growth of large research cohorts, linked to electronic health record (EHR) data, fuels discovery of new genetic variants predicting drug action, supports Mendelian randomization experiments to show drug efficacy, and suggests new indications for existing medications. New biomedical informatics and machine learning approaches advance the ability to interpret clinical information, enabling identification of complex phenotypes and subpopulations of patients. We review the recent history of use of “big data” from EHR-based cohorts and biobanks supporting these activities. Future studies using EHR data, other information sources, and new methods will promote a foundation for discovery to more rapidly advance precision medicine.</p>
</abstract>
</article-meta>
</front>
</article>
</pmc-articleset>